Cost-effectiveness models of non–small cell lung cancer: A systematic literature review
Authors:
- 1 January 2025
- journal article
- review article
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 31 (1) , 69-81
Abstract
Non-small cell lung cancer (NSCLC) presents a formidable global health challenge owing to significant morbidity, high mortality rates, and substantial economic burden. Recent advances in targeted therapies and immunotherapies have transformed NSCLC treatment, but efficacy varies across patients. Tailoring treatment to patients can improve outcomes and potentially improve cost-effectiveness (ie, value for money) as well. For NSCLC, cost-effectiveness must often be estimated using economic modeling, and estimates are only as good as the models. Existing cost-effectiveness models are not necessarily suitable for evaluating personalized medicines. To identify and assess cost-effectiveness models of NSCLC. We searched for studies indexed in PubMed and Embase from 2012 to October 2023 that described cost-effectiveness models of NSCLC. Study details were extracted, summarized, and evaluated for adherence to the Consolidated Health Economic Evaluation Reporting Standards. We identified 237 unique models, 40% of which were published in 2022 or 2023. Despite cross-model heterogeneity, most models used the same 3 health states (progression-free survival, progressive disease, and death) combined with time-to-event equations that characterize risks. Thirty models included a diagnostic component, most of which considered guiding treatment selection using biomarkers. Adherence to the overall Consolidated Health Economic Evaluation Reporting Standards checklist was generally incomplete, and adherence to a subset of model-related questions even more so. The large number of models that were found, almost half of which were published since 2022, underscores the importance of cost-effectiveness analysis in NSCLC. Variable adherence to best practices suggests opportunities for improvement, however, and making high-quality, open-source models available to researchers may be valuable.Keywords
This publication has 39 references indexed in Scilit:
- Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness AnalysisBioDrugs, 2023
- Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in SwedenApplied Health Economics and Health Policy, 2023
- Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050JAMA Oncology, 2023
- The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With ImmunotherapyClinical Lung Cancer, 2023
- Successful combination of database search and snowballing for identification of primary studies in systematic literature studiesInformation and Software Technology, 2022
- Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature ReviewPharmacoEconomics, 2021
- Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung CancerJAMA Oncology, 2020
- Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value ProjectPharmacoEconomics, 2019
- Bayesian models for cost‐effectiveness analysis in the presence of structural zero costsStatistics in Medicine, 2013
- A Systematic Review of Economic Evaluations in Second and Later Lines of Therapy for the Treatment of Non-Small Cell Lung CancerApplied Health Economics and Health Policy, 2012